Published • loading... • Updated
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
The offering includes 5.6 million shares and pre-funded warrants, with underwriters able to buy 1.7 million more shares.
- On Monday, IDEAYA Biosciences announced the pricing of a public offering of common stock and pre-funded warrants, expecting gross proceeds of approximately $300.0 million.
- IDEAYA set the public offering price at $27.00 per share for 5,555,556 common shares, while pre-funded warrants are priced at $26.9999 each with an exercise price of $0.0001 per share.
- Serving as joint book-running managers are J.P. Morgan, Jefferies, TD Securities, UBS Investment Bank, and Cantor, with Wedbush PacGrow acting as the lead manager.
- The offering is expected to close on or about Wednesday, June 10, 2026, and IDEAYA granted underwriters a 30-day option to purchase up to an additional 1,666,669 shares.
- IDEAYA aims to advance its pipeline of synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications in precision oncology.
Insights by Ground AI
23 Articles
23 Articles
Aspen Daily News+22 Reposted by 22 other sources
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 5,555,556 shares of common stock and pre-funded warrants to…
Coverage Details
Total News Sources23
Leaning Left1Leaning Right0Center11Last UpdatedBias Distribution92% Center
Bias Distribution
- 92% of the sources are Center
92% Center
C 92%
Factuality
To view factuality data please Upgrade to Premium
